Takashi Nishimura

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells

Hidemitsu Kitamura, Kenji Iwakabe, Takashi Yahata et al. · The Journal of Experimental Medicine · 1999 · 620 citations · Full text

Life Sciences, Cell Biology, Immunology +14

α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C

Yasuhiro Asahina, Kaoru Tsuchiya, Takashi Nishimura et al. · Hepatology · 2013 · 250 citations · Full text

Medicine, Oncology, Pathology +17

Local Radiation Therapy Inhibits Tumor Growth through the Generation of Tumor-Specific CTL: Its Potentiation by Combination with Th1 Cell Therapy

Tsuguhide Takeshima, Kenji Chamoto, Daiko Wakita et al. · Cancer Research · 2010 · 241 citations · Full text

Medicine, Immunology, Oncology +15

Tumor‐infiltrating IL‐17‐producing γδ T cells support the progression of tumor by promoting angiogenesis

Daiko Wakita, Kentaro Sumida, Yoichiro Iwakura et al. · European Journal of Immunology · 2010 · 234 citations

Life Sciences, Immunology, Oncology +17